Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

- ROS1 +
  - LUN0129 Phase III Study of Highly Selective ROS1 Inhibitor NVL-520 in Advanced NSCLC and Other Solid Tumors (ARROS-1)
    - PI: Neal
    - Sponsor: Nuvant, Inc.
  - LUN012 Phase II Carboblatin + Pemetrexed + Bevacizumab +/- Atezolizumab in Stage IV Non-Squamous NSCLC
    - PI: Wakelee
    - Sponsor: NCTN
  - LUN0128 Phase II Open-Label Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Advanced or Metastatic Solid Tumors including EGFR-Mutated Non-Small Cell Lung Cancer
    - PI: Neal
    - Sponsor: Janssen Research & Development, LLC
  - ECOG-ACRIN-EA5182 Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment in Metastatic EGFR-Mutant NSCLC
    - PI: Neal
    - Sponsor: ECOG-ACRIN
  - PD-L1 Low
    - LUN0131 Phase II Dose-Escalation & Expansion Study of the Safety & Efficacy of XL092 in Combo w/ Immuno-Oncology Agents in Unresectable Advanced or Metastatic Solid Tumors
      - PI: Neal
      - Sponsor: Exelixis, Inc.
    - Without Actionable Genomic Alterations
      - LUN0125 Phase II Sacituzumab Govitecan Combinations in First Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer Without Actionable Genomic Alterations
        - PI: Neal
        - Sponsor: Gilead Sciences, Inc.

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu